We are proud to announce the successful completion of the first preclinical steps for 18F-Flutrahexin, a new fluorine-18 labeled PET tracer analog of 68Ga-Trivehexin, developed together with TRIMT GmbH. This innovation holds great promise for advancing the diagnostics of cancers like pancreatic, lung, head and neck, and ovarian cancers.

In addition to diagnostics, 18F-Flutrahexin opens up new possibilities for therapeutic applications using beta and alpha-emitting radionuclides, such as iodine-131 (131I) and astatine-211 (211At). We’re actively looking for partnerships to move this technology forward to the clinical stage.

Let’s explore new frontiers in cancer treatment and diagnostics together!🌟

Press Release – Tetrakit and TRIMT PDF: https://tetrakit.com/wp-content/uploads/2025/06/Press-Release-Tetrakit-and-TRIMT-PDF.pdf